Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.68 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646134 | 0.88 | MAPK14 (0.73) | MAPK14MAPK11GSK3B | |
| SCHEMBL13646135 | 0.88 | MAPK14 (0.73) | MAPK14MAPK11GSK3B | |
| SCHEMBL3864109 | 0.88 | MAPK14 (0.59) | MAPK14MAPK11 | |
| SCHEMBL13646146 | 0.88 | MAPK14 (0.77) | MAPK14MAPK11 | |
| SCHEMBL13646148 | 0.87 | MAPK14 (0.64) | MAPK14MAPK11GSK3B | |
| SCHEMBL13646132 | 0.87 | MAPK14 (0.73) | MAPK14MAPK11GSK3B | |
| SCHEMBL3876871 | 0.82 | MAPK14 (0.81) | MAPK14MAPK11 | |
| SCHEMBL3866322 | 0.81 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL3864479 | 0.80 | MAPK14 (0.70) | MAPK14MAPK11 | |
| SCHEMBL3862903 | 0.78 | MAPK14 (0.60) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601726-B2 | Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601726-B2 | Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601726-B2 | Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K7 | MAPK14 36/4885MAPK11 39/4885GSK3B 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.